At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 12 enrolled
Drug / intervention
AMG 510drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 510 in Subjects of Chinese Descent With Advanced/Metastatic Solid Tumors With KRAS p.G12C Mutation (CodeBreaK 105)
In Brief
A Phase 1 clinical trial evaluating AMG 510 for Advanced/Metastatic Solid Tumors With KRAS p.G12C Mutation. Completed, enrolled 12 participants across 4 sites in 2 countries.
Detailed Summary
To evaluate safety, tolerability, PK, and preliminary efficacy of AMG 510 PO QD in subjects of Chinese descent with KRAS p.G12C-mutant advanced/metastatic solid tumors.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesHong Kong, Taiwan
Collaborators--
Timeline
Phase 1CompletedFinished
202120222023202420252026
Enrollment StartApr 2020
First PostedMay 2020
Primary CompletionDec 2021
Study CompletionFeb 2026
TodayJul 2026
First PostedMay 8, 2020
Enrollment StartApr 28, 2020
Primary CompletionDec 31, 2021
Study CompletionFeb 9, 2026
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 6.1 years ago
Interventions
AMG 510drug
Subjects will be enrolled and will receive AMG 510 PO QD.